Biochemical and pharmacokinetic characterisation of two PEGylated variants of dipetarudin

Summary

Dipetarudin was coupled to polyethylene glycol (PEG)-5000 residues in order to improve its pharmacokinetic profile and to enhance its anticoagulant efficacy. The resulting compounds, mono-and di-PEGylated dipetarudin were purified by gel filtration. Mono-PEGylated dipetarudin exhibited similar activity like its non-conjugated equivalent both in vitro and in vivo. However, di-PEGylated dipetarudin showed longer distribution and elimination half-lives and higher area under the time-concentration curve in comparison with the unmodified inhibitor which may be attributed to decreased renal clearance. Futhermore, ratio k ₁₂/k ₂₁ decreased when the number of PEG chains coupled to dipetarudin increased. It means that the intercompartment transfer of dipetarudin, characterised by a fast distribution and a high retention in the peripheral compartment, is reverted by coupling to PEG. Thus, the transfer of mono-PEGylated dipetarudin between these compartments is similar in both senses and the transfer of di-PEGylated dipetarudin is slower from vascular to extravascular compartment than vice versa. Our results show that di-PEGylated dipetarudin produces a better and longer anticoagulant effect than unmodified dipetarudin which is a desirable attribute for future therapeutic application.

Keywords

Polyethylene glycol - dipetarudin - thrombin inhibitor - pharmacokinetics

• References

• 1 Mende K, Petoukhova O, Koulitchkova V. et al. Dipetalogastin, a potent thrombin inhibitor from the blood-sucking insect Dipetalogaster maximus. Eur J Biochem 1999; 266: 583-590.
• 2 Lopez M, Mende K, Steinmetzer T. et al. Cloning, purification and biochemical characterization of dipetarudin, a new chimeric thrombin inhibitor. J Chrom B 2003; 786: 73-80.
• 3 Lopez M, Nowak G. Special pharmacokinetics of dipetarudin suggest a potential antitumor activity of this thrombin inhibitor. Anti Cancer Drugs 2004; 15: 145-149.
• 4 Kozlowski A, Harris J. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 2001; 72: 217-224.
• 5 Veronese F, Mero A. The Impact of PEGylation on Biological Therapies. BioDrugs 2008; 22: 315-329.
• 6 Marcus Y, Sasson K, Fridkin M. et al. Turning lowmolecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin. J Med Chem 2008; 51: 4300-4305.
• 7 Lee K, Chae S, Kim T. et al. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 2009; 152: 101-107.
• 8 Stennicke H, Ostergaard H, Bayer R. et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-928.
• 9 Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 1990; 144: 209-213.
• 10 Chapman A, Antoniw P, Spitali M. et al. Therapeutic antibody fragments with prolonged in vivo halflives. Nat Biotechnol 1999; 17: 780-783.
• 11 Yang Z, Wang J, Lu Q. et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004; 64: 6673-6678.
• 12 Lee SH, Lee S, Youn YS. et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 2005; 16: 377-382.
• 13 Nojima Y, Suzuki Y, Iguchi K. et al. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug Chem 2008; 19: 2253-2259.
• 14 Lopez M, Koehler A, Nowak G. High-level secretion of dipetarudin, a chimeric thrombin inhibitor, by Pichia pastoris. Protein Expr Purif 2007; 52: 8-13.
• 15 Dang Q, Di Cera E. A simple activity assay for thrombin and hirudin. J Protein Chem 1994; 13: 367-373.
• 16 Lange U, Keilholz W, Schaub GA, Landmann H, Markwardt F, Nowak G. Biochemical characterization of a thrombin inhibitor from the bloodsucking bug Dipetalogaster maximus. Haemostasis 1999; 29: 204-211.
• 17 Stone S, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628.
• 18 Morrison J, Stone S. Approaches to the study and analysis of the inhibition of enzymes by slow and tight binding inhibitors. Comm Mol Cell Biophys 1985; 02: 347-368.
• 19 Williams J, Morrison J, Duggleby R. Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 1979; 18: 2567-2573.
• 20 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202.
• 21 Yamamoto Y, Tsutsumi Y, Yoshioka Y. et al. Sitespecific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003; 21: 546-552.
• 22 Monkarsh SP, Ma Y, Aglione A. et al. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem 1997; 247: 434-440.
• 23 Yoshioba Y, Tsutsumi Y, Ikemizu S. et al. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem Biophys Res Commun 2004; 315: 808-814.
• 24 Tsutsumi Y, Onda M, Nagata S. et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000; 97: 8548-8553.
• 25 Lopez M, Nowak G. Characterization of the urinary metabolites of dipetarudin. J Chrom B 2005; 821: 210-214.
• 26 Komatsu Y, Hayashi H. Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats. Peptides 1999; 20: 1401-1409.
• 27 Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialysers. Nephrol Dial Transplant 1999; 14: 2922-2926.
• 28 Nowak G, Bucha E. Toxic blood levels of PEG-Hirudin can be antagonized by PMMA dialyzers in vivo. Ann Hematol 2002; 81 (Suppl. 01) A59.